These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25241995)

  • 1. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer.
    Trip AK; Nijkamp J; van Tinteren H; Cats A; Boot H; Jansen EP; Verheij M
    Radiother Oncol; 2014 Aug; 112(2):289-94. PubMed ID: 25241995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.
    Boda-Heggemann J; Hofheinz RD; Weiss C; Mennemeyer P; Mai SK; Hermes P; Wertz H; Post S; Massner B; Hieber U; Hochhaus A; Wenz F; Lohr F
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1187-95. PubMed ID: 19409725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.
    Minn AY; Hsu A; La T; Kunz P; Fisher GA; Ford JM; Norton JA; Visser B; Goodman KA; Koong AC; Chang DT
    Cancer; 2010 Aug; 116(16):3943-52. PubMed ID: 20564136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
    Chakravarty T; Crane CH; Ajani JA; Mansfield PF; Briere TM; Beddar AS; Mok H; Reed VK; Krishnan S; Delclos ME; Das P
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):581-6. PubMed ID: 22137021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques.
    Milano MT; Garofalo MC; Chmura SJ; Farrey K; Rash C; Heimann R; Jani AB
    Br J Radiol; 2006 Jun; 79(942):497-503. PubMed ID: 16714752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach.
    Wieland P; Dobler B; Mai S; Hermann B; Tiefenbacher U; Steil V; Wenz F; Lohr F
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1236-44. PubMed ID: 15234061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
    Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
    Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
    Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
    Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
    Jansen EP; Boot H; Dubbelman R; Bartelink H; Cats A; Verheij M
    Br J Cancer; 2007 Sep; 97(6):712-6. PubMed ID: 17848909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.
    Quero L; Bouchbika Z; Kouto H; Baruch-Hennequin V; Gornet JM; Munoz N; Cojean-Zelek I; Houdart R; Panis Y; Valleur P; Aparicio T; Maylin C; Hennequin C
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):574-80. PubMed ID: 22099038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited advantages of intensity-modulated radiotherapy over 3D conformal radiation therapy in the adjuvant management of gastric cancer.
    Alani S; Soyfer V; Strauss N; Schifter D; Corn BW
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):562-6. PubMed ID: 19427558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
    DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
    Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
    Welz S; Hehr T; Kollmannsberger C; Bokemeyer C; Belka C; Budach W
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1429-35. PubMed ID: 17692474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy.
    Liu GF; Bair RJ; Bair E; Liauw SL; Koshy M
    PLoS One; 2014; 9(1):e82642. PubMed ID: 24416146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
    Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
    Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.
    Boda-Heggemann J; Weiss C; Schneider V; Hofheinz RD; Haneder S; Michaely H; Wertz H; Ronellenfitsch U; Hochhaus A; Wenz F; Lohr F
    Strahlenther Onkol; 2013 May; 189(5):417-23. PubMed ID: 23558673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
    Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
    J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT.
    Münch S; Aichmeier S; Hapfelmeier A; Duma MN; Oechsner M; Feith M; Combs SE; Habermehl D
    Strahlenther Onkol; 2016 Oct; 192(10):722-9. PubMed ID: 27418129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy.
    Ito M; Kodaira T; Tachibana H; Tomita N; Makita C; Koide Y; Kato D; Abe T; Muro K; Tajika M; Niwa Y; Hasegawa Y
    Head Neck; 2017 Dec; 39(12):2406-2415. PubMed ID: 28960561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.